Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medela Potentia Tbk. (MDLA.JK)
Jakarta Selatan, ID
PT Medela Potentia Tbk produces and distributes a wide range of pharmaceutical and healthcare products throughout Indonesia and Cambodia. Its offerings include medical devices, spanning from consumable supplies to specialized equipment for hospitals and laboratories. The company also operates the GoApotik.com digital platform, an online channel that makes its products available to retailers, direct consumers, and patients. Founded in 2011, the firm is headquartered in Jakarta Selatan, Indonesia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.99% | +0.99% | -5.56% | -15.00% | -19.05% | -22.73% | +0.00% | +8.51% | +8.51% | +8.51% | +8.51% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+2.2% Q1'26: +6.7% (vs Q4'24)
-
EPS growth Medical - Distribution: +4.9%-19.8% Q1'26: -9.4% (vs Q4'24)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+2.7% Q1'26: -6.1% (vs Q4'24)
-
EBIT margin Medical - Distribution: +3.0%+3.5% ★ Q1'26: +3.2% (vs Q4'24)
-
ROIC Medical - Distribution: +5.7%+18.6% ★ Q1'26: +15.5% (vs Q4'24)
-
Share dilution Medical - Distribution: +0.0%+41.7% Q1'26: +41.7% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.13× ★ Q1'26: 0.13× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|
| Revenue |
14.89T
est: 14.73T (+1.1%)
|
15.68T
15.68T – 15.68T
+6.5% YoY
|
16.89T
16.89T – 16.89T
+7.7% YoY
|
| EBITDA |
605.23B
est: 587.42B (+3.0%)
|
625.48B
625.48B – 625.48B
+6.5% YoY
|
673.75B
673.75B – 673.75B
+7.7% YoY
|
| EBIT |
525.31B
est: 506.80B (+3.7%)
|
539.64B
539.64B – 539.64B
+6.5% YoY
|
581.29B
581.29B – 581.29B
+7.7% YoY
|
| Net Income |
392.27B
est: 389.42B (+0.7%)
|
406.37B
406.37B – 406.37B
+4.4% YoY
|
442.03B
434.40B – 449.67B
+8.8% YoY
|
| SGA |
408.90B
est: 495.49B (-17.5%)
|
527.59B
527.59B – 527.59B
+6.5% YoY
|
568.30B
568.30B – 568.30B
+7.7% YoY
|
| EPS |
27.99
est: 27.79 (+0.7%)
|
29.00
29.00 – 29.00
+4.4% YoY
|
31.55
31.00 – 32.09
+8.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-25 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Krestijanto Pandji | President Director | — | male |
| Santi Dewi | Corporate Secretary | — | — |
| Tresno Dhiwangkara | Head of the Internal Audit Unit | — | male |
| Wimala Widjaja | Corporate Secretary & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MDLA.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
